FibroFighters had a great opportunity to show off our research at the largest and most important oncology meeting in the world: the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. It was held this year in Chicago from June 2-6.
Of the 5,760 Abstracts, posters, and papers accepted, only five were about Fibrolamellar Hepatocellular Carcinoma. Of those five, four were from FibroFighters and one was from MD Anderson (describing the 3 patients on their clinical trial for FLC who became surgical candidates).
We were all very glad we had the opportunity to present this important work and spread awareness within the medical community about FLC. Below we have the abstracts and posters presented at ASCO this year – many of YOU contributed to these data (and we thank you!).
(1) You have heard of the FibroFighters Multidisciplinary Tumor Board; after less than a year, we have discussed more than 80 different FLC patients with their primary teams. Here are the results of the first 59: Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.
(2) FibroFighters has collaborated with “Signatera” for tracking the DNA from your tumor in your blood: First report of tumor-informed circulating tumor DNA in fibrolamellar carcinoma in adolescents and young adults: 51 patients.
(3) FibroFighters also collaborates with the Nagourney Cancer Institute – a CLIA approved lab – which performs testing of fresh live cells from the FLC tumor to see what combinations of drugs work best: Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.
(4) We often hear “there are no proven systemic therapies for FLC.” Because of how the system currently works, we have waited for years and will likely wait years longer to get definitive proof from phase 3 controlled FLC trials. Until then, for those suffering now, we have compelling evidence for systemic therapy, and particularly for converting unresectable patients into resectable patients: This cohort of 29 young adults is the largest set of FLC patients on a systemic therapy. Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.
